Literature DB >> 26719528

STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis.

Laura M Jones1, Miranda L Broz2, Jill J Ranger1, John Ozcelik3, Ryuhjin Ahn4, Dongmei Zuo1, Josie Ursini-Siegel4, Michael T Hallett3, Matthew Krummel2, William J Muller5.   

Abstract

Immunosurveillance constitutes the first step of cancer immunoediting in which developing malignant lesions are eliminated by antitumorigenic immune cells. However, the mechanisms by which neoplastic cells induce an immunosuppressive state to evade the immune response are still unclear. The transcription factor STAT3 has been implicated in breast carcinogenesis and tumor immunosuppression in advanced disease, but its involvement in early disease development has not been established. Here, we genetically ablated Stat3 in the tumor epithelia of the inducible PyVmT mammary tumor model and found that Stat3-deficient mice recapitulated the three phases of immunoediting: elimination, equilibrium, and escape. Pathologic analyses revealed that Stat3-deficient mice initially formed hyperplastic and early adenoma-like lesions that later completely regressed, thereby preventing the emergence of mammary tumors in the majority of animals. Furthermore, tumor regression was correlated with massive immune infiltration into the Stat3-deficient lesions, leading to their elimination. In a minority of animals, focal, nonmetastatic Stat3-deficient mammary tumors escaped immune surveillance after a long latency or equilibrium period. Taken together, our findings suggest that tumor epithelial expression of Stat3 plays a critical role in promoting an immunosuppressive tumor microenvironment during breast tumor initiation and progression, and prompt further investigation of Stat3-inhibitory strategies that may reactivate the immunosurveillance program. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26719528      PMCID: PMC5052827          DOI: 10.1158/0008-5472.CAN-15-2770

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.

Authors:  Nills Diaz; Susan Minton; Charles Cox; Tammy Bowman; Tanya Gritsko; Roy Garcia; Ibrahim Eweis; Marek Wloch; Sandy Livingston; Ed Seijo; Alan Cantor; Ji-Hyun Lee; Craig A Beam; Daniel Sullivan; Richard Jove; Carlos A Muro-Cacho
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis.

Authors:  Lingyan Wu; Hong Du; Yuan Li; Peng Qu; Cong Yan
Journal:  Am J Pathol       Date:  2011-08-22       Impact factor: 4.307

4.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

5.  Essential role of STAT3 for embryonic stem cell pluripotency.

Authors:  R Raz; C K Lee; L A Cannizzaro; P d'Eustachio; D E Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

6.  Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression.

Authors:  Keisuke Hagihara; Teppei Nishikawa; Yasuhiro Sugamata; Jian Song; Tomoyasu Isobe; Tetsuya Taga; Kazuyuki Yoshizaki
Journal:  Genes Cells       Date:  2005-11       Impact factor: 1.891

Review 7.  The role of C/EBPbeta in mammary gland development and breast cancer.

Authors:  Sandra L Grimm; Jeffrey M Rosen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

8.  Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.

Authors:  Todd M Savarese; Cara L Campbell; Catherine McQuain; Kathryn Mitchell; Rachel Guardiani; Peter J Quesenberry; Beth E Nelson
Journal:  Cytokine       Date:  2002-03-21       Impact factor: 3.861

9.  Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.

Authors:  Maria Libera Ascierto; Michael O Idowu; Yingdong Zhao; Hanif Khalak; Kyle K Payne; Xiang-Yang Wang; Catherine I Dumur; Davide Bedognetti; Sara Tomei; Paolo A Ascierto; Anil Shanker; Harry D Bear; Ena Wang; Francesco M Marincola; Andrea De Maria; Masoud H Manjili
Journal:  J Transl Med       Date:  2013-06-12       Impact factor: 5.531

10.  TLR9 ligands induce S100A8 in macrophages via a STAT3-dependent pathway which requires IL-10 and PGE2.

Authors:  Kenneth Hsu; Yuen Ming Chung; Yasumi Endoh; Carolyn L Geczy
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

View more
  43 in total

1.  Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.

Authors:  Xiaowei Chen; Yoshihiro Takemoto; Huan Deng; Moritz Middelhoff; Richard A Friedman; Timothy H Chu; Michael J Churchill; Yan Ma; Karan K Nagar; Yagnesh H Tailor; Siddhartha Mukherjee; Timothy C Wang
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

2.  Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells.

Authors:  Kimberly M Arnold; Lynn M Opdenaker; Nicole J Flynn; Daniel Kwesi Appeah; Jennifer Sims-Mourtada
Journal:  Int J Radiat Biol       Date:  2020-01-06       Impact factor: 2.694

Review 3.  Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications.

Authors:  Johann S Bergholz; Qiwei Wang; Sheheryar Kabraji; Jean J Zhao
Journal:  Clin Cancer Res       Date:  2020-06-23       Impact factor: 12.531

4.  Receptor interacting protein 1 knockdown induces cell death in liver cancer by suppressing STAT3/ATR activation in a p53-dependent manner.

Authors:  Seung-Youn Jung; Jeong-In Park; Jae-Hoon Jeong; Kyung-Hee Song; Jiyeon Ahn; Sang-Gu Hwang; Jaesung Kim; Jong-Kuk Park; Dae-Seog Lim; Jie-Young Song
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

Review 5.  Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.

Authors:  Todd A Aguilera; Amato J Giaccia
Journal:  Clin Cancer Res       Date:  2017-03-13       Impact factor: 12.531

6.  Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling.

Authors:  Rebecca S DeVaux; Ali S Ropri; Sandra L Grimm; Peter A Hall; Emilio O Herrera; Sridar V Chittur; William P Smith; Cristian Coarfa; Fariba Behbod; Jason I Herschkowitz
Journal:  J Cell Biochem       Date:  2020-01-07       Impact factor: 4.429

Review 7.  The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease.

Authors:  Shih-Ying Wu; Kounosuke Watabe
Journal:  Front Biosci (Landmark Ed)       Date:  2017-06-01

Review 8.  Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.

Authors:  Jing Jin; Yi Li; Qijie Zhao; Yue Chen; Shaozhi Fu; JingBo Wu
Journal:  Cell Commun Signal       Date:  2021-05-06       Impact factor: 5.712

Review 9.  Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes.

Authors:  Monikaben Padariya; Alicja Sznarkowska; Sachin Kote; Maria Gómez-Herranz; Sara Mikac; Magdalena Pilch; Javier Alfaro; Robin Fahraeus; Ted Hupp; Umesh Kalathiya
Journal:  Biomolecules       Date:  2021-04-22

10.  Chitosan promotes immune responses, ameliorates glutamic oxaloacetic transaminase and glutamic pyruvic transaminase, but enhances lactate dehydrogenase levels in normal mice in vivo.

Authors:  Ming-Yang Yeh; Yung-Luen Shih; Hsueh-Yu Chung; Jason Chou; Hsu-Feng Lu; Chia-Hui Liu; Jia-You Liu; Wen-Wen Huang; Shu-Fen Peng; Lung-Yuan Wu; Jing-Gung Chung
Journal:  Exp Ther Med       Date:  2016-02-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.